AN2 Therapeutics, Inc. Current Assets
AN2 Therapeutics, Inc. (ANTX) had Current Assets of $79.99 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AssetsCurrent · last filed 2026-08-11
- 2026-06-30: Assets, Current $79.99M.
- 2026-03-31: Assets, Current $87.49M.
- 2025-12-31: Assets, Current $59.94M.
- 2025-09-30: Assets, Current $64.02M.
| Period end | Assets, Current |
|---|---|
| 2026-06-30 | $79.99M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $87.49M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $59.94M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $64.02M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $67.52M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $69.56M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $86.26M 10-K · filed 2026-03-17 |
| 2024-09-30 | $97.69M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $107.44M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $116.31M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $110.51M 10-K · filed 2025-03-25 |
| 2023-09-30 | $126.41M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $98.21M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $90.32M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $98.62M 10-K · filed 2024-03-29 |
| 2022-09-30 | $107.30M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $116.88M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $119.78M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $60.11M 10-K · filed 2023-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |